An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients

NCT01725529 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

457

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: TMC435
DRUG: Peginterferon-alpha (PegIFNα-2a)
DRUG: Ribavirin (RBV)
DRUG: Placebo

Sponsor

Janssen R&D Ireland